Gapping up
In reaction to strong earnings/guidance:
- KMX +3.2%, HOME +0.8%
Other news:
- TLSA +17.7% (receives first-ever patent on a transformational technology for oral delivery of all anti-CD3 monoclonal antibodies)
- AMC +10.1% (to resume theatre operations on Wednesday, July 15)
- MPC +8.2% (WSJ report that co is in discussions with buyers for its Speedway unit)
- TWO +7.1% (raises dividend)
- DVAX +5.2% (initiates Phase 1 clinical trial for COVID-19 vaccine candidate)
- CHMI +5% (lowers dividend)
- CLCT +4.7% (Alta Fox to nominate slate of six highly qualified director candidates for election at Collectors Universe's 2020 annual meeting)
- CLR +4% (provides update on voluntary production curtailments)
- PENN +3.6% (has resumed operations at more than 70% of the company's 41 properties)
- EVA +2.2% (increases distribution guidance for 2020)
- SNY +2.2% (Sanofi and Regeneron (REGN) announce that Dupixent was approved in China for adults with moderate-to-severe atopic dermatitis)
- DDOG +2.1% (announces FedRAMP authorization for low-impact SaaS)
- CRY +1.9% (prices $100 mln 4.250% convertible senior notes due 2025 - estimates that it will receive ~$96.5 mln in net proceeds)
- ASMB +1.5% (regains rights to all microbiome gastrointestinal programs as AbbVie terminates agreement)
- BGNE +1.5% (reports China National Medical Products Administration has accepted a supplemental new drug application of its anti-PD-1 antibody tislelizumab in combination with chemotherapy)
Analyst comments:
- RYAM +12.2% (upgraded to Buy from Underperform at BofA/Merrill)
- DT +6.3% (upgraded to Buy from Neutral at Goldman)
- OXY +6% (upgraded to Buy from Hold at SunTrust)
- ULTA +3.2% (upgraded to Overweight from Equal Weight at Barclays)
- SPOT +3.2% (target raised to Street-high $275 at Rosenblatt)
- AAPL +0.9% (target raised to $405 from $370 at Jefferies on 5G cycle confidence)